Welcome to our dedicated page for Repare Therapeutics news (Ticker: RPTX), a resource for investors and traders seeking the latest updates and insights on Repare Therapeutics stock.
Repare Therapeutics Inc (RPTX) is a clinical-stage biotechnology company pioneering precision oncology therapies through its synthetic lethality platform and CRISPR-enabled target discovery. This page aggregates official announcements, research breakthroughs, and strategic developments critical for understanding the company's progress in developing targeted cancer treatments.
Investors and researchers will find comprehensive updates on clinical trial milestones, regulatory filings, and scientific collaborations. The curated news collection includes updates on therapeutic candidates, partnership agreements, and peer-reviewed research findings, providing a centralized hub for tracking RPTX's contributions to oncology innovation.
Key content areas cover clinical-stage developments, research publications, and strategic partnerships that demonstrate the company's scientific rigor. All materials are sourced from verified corporate communications and reputable industry publications to ensure reliability.
Bookmark this page for streamlined access to Repare Therapeutics' latest advancements in CRISPR-based drug discovery and precision oncology solutions. Check back regularly for real-time insights into their mission to develop therapies targeting genetic vulnerabilities in cancer cells.
Repare Therapeutics presented initial data from its ongoing Phase 1/2 TRESR clinical trial for camonsertib (RP-3500), an ATR inhibitor, in combination with PARPis at the 2023 AACR Annual Meeting. The trials show a 48% clinical benefit rate across various tumor types, especially in late-line ovarian cancer with a 58% clinical benefit rate and a median progression-free survival of about 7 months. Early ctDNA responses indicated a strong antitumor activity, with 66% of evaluable patients responding positively. The treatment showed a favorable safety profile with manageable toxicities. Repare is focused on optimizing doses and expanding studies in different tumor types as part of its collaboration with Roche.
Repare Therapeutics Inc. (Nasdaq: RPTX) announced that data from Phase I/II trials of camonsertib in combination with PARP inhibitors has been selected for presentation at the 2023 AACR Annual Meeting in Orlando, Florida, from April 14-19, 2023. The presentation will highlight safety and efficacy results in patients with solid tumors with DNA damage response alterations, featuring Dr. Timothy Yap. Additionally, two poster presentations will characterize genomic features in ovarian and uterine cancers. Repare's SNIPRx® platform enables the development of precision oncology therapies targeting genomic instability, showcasing its commitment to innovative cancer treatment.
Repare Therapeutics reported its financial results for Q4 and full year 2022, emphasizing growth in its oncology pipeline. The company secured a collaboration with Roche for camonsertib, received FDA Fast Track designation for RP-6306, and expects significant clinical trial data in 2023. Revenue from collaboration agreements rose to $131.8 million in 2022, up from $7.6 million in 2021. Net loss was $31.7 million for Q4 2022, marking an increase from $28.3 million in Q4 2021. Cash and equivalents totaled $343.9 million, projected to support operations until 2026. Repare plans to advance multiple clinical programs throughout 2023.
Repare Therapeutics Inc. (Nasdaq: RPTX) announced its participation in two investor conferences: the Guggenheim Oncology Conference on February 9, 2023, at 3:20 p.m. ET in New York, and the Cowen 43rd Annual Health Care Conference on March 8, 2023, at 9:50 a.m. ET in Boston. Investors can access live webcasts of the events via the Company’s website, with replays available for 30 days. Repare is focused on precision oncology, using its proprietary SNIPRx® platform for developing targeted cancer therapies, including ongoing Phase 1 trials of RP-6306 and camonsertib (RP-3500), and additional preclinical programs.
Repare Therapeutics Inc. (NASDAQ: RPTX) announced a $1.5 million research service payment from Ono Pharmaceutical Co., Ltd. This payment is part of their 2019 Strategic Partnership Agreement, linked to the Polθ program (RP-2119). The funding indicates a key milestone as Repare progresses towards IND-enabling studies and prepares for clinical trials anticipated to start in summer 2023. To date, the Ono Agreement has facilitated approximately $8.1 million in funding for Repare, evidencing ongoing collaboration and financial support for its oncology research initiatives.
Repare Therapeutics Inc. (RPTX) announced the establishment of Automatic Securities Disposition Plans (ASDPs) for its executives, allowing them to sell up to 422,512 common shares over approximately 15 months. This move complies with U.S. and Canadian regulations, ensuring trades occur only when the executives do not possess any material non-public information. The ASDPs provide structured selling parameters while limiting amendments to prevent insider trading advantages. The company is focused on precision oncology, utilizing its SNIPRx® platform to develop therapies for genomic instability.
Repare Therapeutics reported Q3 2022 financial results, achieving a net income of $75.5 million, or $1.71 per diluted share, compared to a net loss of $30.9 million the previous year. The company holds $370.4 million in cash, sufficient to fund operations into 2026. Key developments include advancing RP-6306 in Phase 1 trials, with early data expected in H1 2023, and a collaboration with Roche for camonsertib, which includes a $125 million upfront payment and potential total milestone payments up to $1.172 billion.
Repare Therapeutics Inc. (NASDAQ: RPTX) has announced participation at two upcoming investor conferences in November 2022. The first is the H.C. Wainwright 3rd Annual Precision Oncology Virtual Conference on November 14 at 10:00 a.m. ET. The second is the Piper Sandler 34th Annual Healthcare Conference on November 29 at 3:00 p.m. ET, taking place in New York, NY. Investors can access live webcasts of both events on the Company’s website, with replays available for 90 days. Repare focuses on precision oncology and utilizes its proprietary SNIPRx® platform for novel cancer therapies.
Repare Therapeutics Inc. (NASDAQ: RPTX) will participate in two investor conferences in September 2022. The first event is the Morgan Stanley 20th Annual Global Healthcare Conference on September 14 at 2:55 p.m. ET in New York. The second is the Guggenheim Nantucket Therapeutics Conference on September 28 at 8:00 a.m. ET in Nantucket, MA. Live webcasts will be available on the company’s website, and replays will be accessible for 90 days. Repare focuses on precision oncology, utilizing its SNIPRx® platform to develop targeted cancer therapies.
Repare Therapeutics has signed a worldwide license and collaboration agreement with Roche for camonsertib (RP-3500) aimed at advanced solid tumors. Repare received a $125 million upfront payment and could earn up to $1.172 billion in milestones, plus royalties on global sales. The company expects clinical data for RP-6306 in early 2023, having initiated IND-enabling studies for RP-2119. Financial results show a net loss of $38.1 million for Q2 2022, up from $26.3 million in Q2 2021, despite increased R&D investments aimed at advancing its oncology pipeline.
